BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

Overview
Date Founded

1991

Headquarters

2190 Parkway Lake Drive,Birmingham, AL 35244

Type of Company

Public

Employees (Worldwide)

140

Industries

Biotechnology
Pharmaceuticals
Medical Support Services

Company Description

Founded in 1986, BioCryst has approximately 38 employees between the Company’s headquarters in Durham, North Carolina and its Discovery Center of Excellence in Birmingham, Alabama. With expertise in drug discovery, clinical development and regulatory affairs, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. We are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. The commitment of BioCryst has remained unchanged. We continue to be passionate about advancing novel therapeutics for patients with serious diseases.

Contact Data
Trying to get in touch with decision makers at BioCryst Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President, Chief Executive Officer, Director

Senior Vice President & Chief Financial Officer

Chief Commercial Officer

Senior Vice President, Chief Legal Officer & Corporate Secretary

Senior Vice President & Chief Medical Officer

Chief Business Officer & Senior Vice President

Senior Vice President, Drug Discovery

Independent Business Owner

Executive Director

Executive Director of Product Safety

Board of Directors

General Partner at Hatteras Venture Partners

General Partner at Hatteras Venture Partners

Owner at Standing Stones Farm

President, Chief Executive Officer, Director at BioCryst Pharmaceuticals, Inc.

Editorial Advisor at Journal of Accountancy

Chief Executive Officer at Kyalin Biosciences, Inc.

Former Senior Vice President & Chief Commercial Officer at Innoviva, Inc.

Senior Vice President, Clinical Development & Chief Medical Officer at GlycoMimetics, Inc.

Chief Executive Officer at Freeline Therapeutics Ltd.

Paths to BioCryst Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
BioCryst Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Sarissa Capital Management seeks to achieve superior risk-adjusted returns by constructing a portfolio, primarily across healthcare and related sectors, where there is a significant discrepancy between market value and intrinsic value. They frequently use activism to close this discrepancy. The firm employs a fundamental, research-driven, value-oriented approach to identify potential investments. Sarissa Capital Management conducts rigorous, fundamentals-based research. The funds’ portfolios will consist largely of exchange-traded securities (mostly equities but including equity-linked derivatives such as total return swaps and options), but the funds may also invest in a broad range of other financial instruments including, but not limited to, over-the-counter (OTC) equity securities and equity linked derivatives such as total return swaps and options (including index funds), privately placed securities of public issuers, preferred stock, currencies and fixed income securities (including credit default swaps).

Details Hidden

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment and philanthropy—all toward the end goal of cures for disease, improved quality of life and reduced cost of care. As of late 2019, the firm manages nearly $10 billion in assets. Providing value beyond capital, Deerfield generally maintains a combined portfolio of more than 200 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company. Having many years of operational expertise, Deerfielders are highly engaged and adept at navigating the complex crosscurrents ever-present in the healthcare and financial industries. Collaboration, intellectual curiosity and pragmatism drive Deerfield’s approach. With its holistic view, Deerfield tailors flexible financing options designed to meet the needs of entrepreneurs and corporate partners.

Details Hidden

Oracle Investment Management focuses on long/short investments in the US healthcare sector with an emphasis on pharmaceutical and biotechnology companies. The firm tends to invest in small-cap US companies but they also invest in mid-cap and large-cap companies and in Europe. The firm seeks to achieve strong absolute and risk-adjusted returns on both client and principals capital by anticipating key sub-sector themes and by identifying specific companies within those sub-sectors with unrecognized investment potential. They use fundamental research in their stock selection and maintain a medium turnover rate

Recent Transactions
Details Hidden

BioCryst Pharmaceuticals, Inc. issued . USD Common Stock

Details Hidden

BioCryst Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

BioCryst Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onBioCryst Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onBioCryst Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onBioCryst Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onBioCryst Pharmaceuticals, Inc. issued . USD Common Stock

Professional

Advised onBioCryst Pharmaceuticals, Inc. issued . USD Common Stock

Underwriter

Advised onBioCryst Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Goodwin Procter LLP

Advisor

Chief Financial Officer at Lensar, Inc.

Legal Advisor

Partner at Chadbourne & Parke LLP

Clients

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.

Green Cross Corp. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for blood, over the counter drugs, generals, vaccines, and others. The company was founded on November 1, 1969 and is headquartered in Yongin, South Korea.

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Key Stats and Financials As of 2019
Market Capitalization
$736M
Total Enterprise Value
$346M
Earnings Per Share
$-0.94
Revenue
$48.8M
Net Profit
$-109M
Total Equity
$38.3M
Debt TEV
0.24x
Three Year Compounded Annual Growth Rate Of Revenue
22.83%
Five Year Compounded Annual Growth Rate Of Revenue
29.12%
TEVNet Income
-3.17x
Enterprise Value / Sales
7.08x
Total Debt
$84.7M
EBITDAMargin
-202.17%
EBITDA
$-98.7M
Suppliers
Industrial Research Ltd. Other Business & Consulting Services | Lower Hutt, New Zealand

Industrial Research Ltd. provides research and development services in the manufacturing and service sectors. The company was founded in 1992 and is headquartered in Wellington, New Zealand.

Yeshiva University Schools & Student Services | New York, NY

Yeshiva University has been transforming lives for more than a century. Nowhere but here can students have a personal, small college experience while benefitting from the academic rigor of a top ranked research university. Since its inception YU has been dedicated to melding the ancient traditions of Jewish law and life with the heritage of Western civilization, and each year we celebrate as future leaders make YU their home. More than 6,400 undergraduate and graduate students study at our four New York City campuses: the Wilf Campus, Israel Henry Beren Campus, Brookdale Center and Jack and Pearl Resnick Campus. Our three undergraduate schools—Yeshiva College, Stern College for Women and Syms School of Business—offer a unique dual curriculum comprising Jewish studies and liberal arts and sciences courses. Students also have the option to study in Israel in their first year. Our graduate and affiliate schools include Albert Einstein College of Medicine, Benjamin N. Cardozo School of Law, Wurzweiler School of Social Work, Ferkauf Gradaute School of Psychology, Azrieli Graduate School of Jewish Education and Administration, Bernard Revel Graduate School of Jewish Studies and Rabbi Isaac Elchanan Theological Seminary

University of Alabama, Birmingham Hospitals & Patient Services | Birmingham, AL

The University of Alabama at Birmingham (UAB) is a public university in Birmingham in the U.S. state of Alabama. Developed from an academic extension center established in 1936, the institution became an autonomous institution in 1969 and is today one of three institutions in the University of Alabama System. In the fall of 2013, 18,568 students from more than 110 countries were enrolled at UAB pursuing studies in 140 programs of study in 12 academic divisions leading to bachelor's, master's, doctoral, and professional degrees in the social and behavioral sciences, the liberal arts, business, education, engineering, and health-related fields such as medicine, dentistry, optometry, nursing, and public health.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Alnylam Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, Massachusetts

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by BioCryst Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of BioCryst Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and BioCryst Pharmaceuticals, Inc..